AIDS Deals Heat Up--In Both Private and Public Sectors
Abbott Laboratories' Norvir (ritonavir) set a record early in March: the FDA reviewed and approved the protease inhibitor for use alone or in combination therapy as a treatment for late-stage AIDS just 72 days after filing.
You may also be interested in...
A short discussion of the state of HIV/AIDS research, including drug and vaccine development, reversing AIDS' destructive process, and new studies in this area.
Adding non-transfusion-dependent anemia patients to the Reblozyl label is a key strategy for the product, which BMS expects to reach $4bn in annual sales.
Biogen has warned that uptake for its newly approved Alzheimer’s therapy will be slow in the beginning and doctors confirm it will take time to figure which patients can and should be treated.